Here, we report the three-year survival outcomes of patients with advanced NSCLC who had a PD-L1 TPS of 50% to 89% vs greater than or equal to 90% and received first-line PD-1 inhibition in two independent cohorts, including a multi-institutional, retrospective cohort of patients treated with commercial first-line pembrolizumab and the prospective, randomized, phase III EMPOWER-Lung 1 trial of cemiplimab versus chemotherapy. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.